Author: Patrick van der Valk

New study will collect, organize, and share data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG) research. xCures, a leader in data-driven cancer solutions, is thrilled to announce that its platform has been highlighted as a new commitment to deliver progress on the mission of the White… Read more »

Seamless integration with existing healthcare infrastructures drives unprecedented possibilities to improve medical research and patient care. xCures, a trailblazer in healthcare technology, is delighted to unveil xUTILITY, a solution poised to transform the patient registry paradigm in the United States. xUTILITY establishes an instantaneous patient registry platform by retrieving records… Read more »

xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology. First posted on NewsDirect In a step forward for healthcare research, xCures is pleased to announce that it will support Aetion®’s collaboration with the US Food and Drug Administration (FDA) Oncology… Read more »

xCures’ technology harnesses real-time patient data and makes it accessible for scientific exploration and to improve patient options. Today, xCures and the Diffuse Intrinsic Pontine Glioma (DIPG) / Diffuse Midline Glioma (DMG) Research Funding Alliance (DDRFA) are proud to announce their partnership, a collaboration focused on leveraging real-time patient data… Read more »

CureMatch will leverage the xCures technology that automatically creates a comprehensive outline of a cancer patient’s medical history in order to improve treatment recommendations. CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a partnership with xCures,… Read more »

Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations.  [Oakland, CA, May 26, 2023] – xCures, a healthcare technology company, is pleased to announce its participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, to… Read more »

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to… Read more »

RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »